RCT: Phentermine/Topiramate for the treatment of adolescent obesity.
2 May, 2022 | 00:41h | UTCPhentermine/Topiramate for the Treatment of Adolescent Obesity – NEJM Evidence
Commentary on Twitter
This RCT evaluated phentermine/topiramate in adolescents ages 12 to <17 yrs with high BMIs over a 56 week period. At both mid- and top-doses, treatment significantly reduced BMI and waist circumference compared to placebo. https://t.co/HbCZOAlZPf@PedsEndoSociety #PedsEndo2022 pic.twitter.com/nB5juqxyA0
— NEJM Evidence (@NEJMEvidence) April 30, 2022